IPCALAB Stock Overview
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India.
Ipca Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹896.90|
|52 Week High||₹1,383.10|
|52 Week Low||₹831.05|
|1 Month Change||-0.38%|
|3 Month Change||-15.84%|
|1 Year Change||-11.48%|
|3 Year Change||87.00%|
|5 Year Change||273.71%|
|Change since IPO||2,260.26%|
Recent News & Updates
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
In this article we are going to estimate the intrinsic value of Ipca Laboratories Limited ( NSE:IPCALAB ) by taking the...
|IPCALAB||IN Pharmaceuticals||IN Market|
Return vs Industry: IPCALAB exceeded the Indian Pharmaceuticals industry which returned -16.3% over the past year.
Return vs Market: IPCALAB underperformed the Indian Market which returned 0.6% over the past year.
|IPCALAB Average Weekly Movement||2.9%|
|Pharmaceuticals Industry Average Movement||6.8%|
|Market Average Movement||7.0%|
|10% most volatile stocks in IN Market||9.9%|
|10% least volatile stocks in IN Market||4.5%|
Stable Share Price: IPCALAB is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IPCALAB's weekly volatility (3%) has been stable over the past year.
About the Company
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including cardiology, gastroenterology, dermatology, rheumatology, urology, ophthalmology, infectious disease, immunosuppressant, probiotics, respiratory, allergy, nutraceuticals, anti-neoplastic, malarial, neurology, psychiatry, orthopedics, helminthics, fever, hematology, hepatoprotective, diabetology, anti-epileptic, emollients/protectives, NSAIDs, rheumatology, anti-arthritic, and neuropathic pain, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections.
Ipca Laboratories Fundamentals Summary
|IPCALAB fundamental statistics|
Is IPCALAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IPCALAB income statement (TTM)|
|Cost of Revenue||₹20.15b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||34.85|
|Net Profit Margin||15.16%|
How did IPCALAB perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is IPCALAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPCALAB?
Other financial metrics that can be useful for relative valuation.
|What is IPCALAB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does IPCALAB's PE Ratio compare to its peers?
|IPCALAB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
AJANTPHARM Ajanta Pharma
500660 GlaxoSmithKline Pharmaceuticals
AUROPHARMA Aurobindo Pharma
IPCALAB Ipca Laboratories
Price-To-Earnings vs Peers: IPCALAB is good value based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (32.6x).
Price to Earnings Ratio vs Industry
How does IPCALAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: IPCALAB is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the Indian Pharmaceuticals industry average (21.1x)
Price to Earnings Ratio vs Fair Ratio
What is IPCALAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||25.7x|
|Fair PE Ratio||25.6x|
Price-To-Earnings vs Fair Ratio: IPCALAB is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the estimated Fair Price-To-Earnings Ratio (25.6x).
Share Price vs Fair Value
What is the Fair Price of IPCALAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IPCALAB (₹896.9) is trading below our estimate of fair value (₹1132.83)
Significantly Below Fair Value: IPCALAB is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: IPCALAB is poor value based on its PEG Ratio (1.8x)
Discover undervalued companies
How is Ipca Laboratories forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPCALAB's forecast earnings growth (14.2% per year) is above the savings rate (6.7%).
Earnings vs Market: IPCALAB's earnings (14.2% per year) are forecast to grow slower than the Indian market (17.3% per year).
High Growth Earnings: IPCALAB's earnings are forecast to grow, but not significantly.
Revenue vs Market: IPCALAB's revenue (10.5% per year) is forecast to grow slower than the Indian market (11.5% per year).
High Growth Revenue: IPCALAB's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPCALAB's Return on Equity is forecast to be low in 3 years time (16.8%).
Discover growth companies
How has Ipca Laboratories performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPCALAB has high quality earnings.
Growing Profit Margin: IPCALAB's current net profit margins (15.2%) are lower than last year (21%).
Past Earnings Growth Analysis
Earnings Trend: IPCALAB's earnings have grown significantly by 26.2% per year over the past 5 years.
Accelerating Growth: IPCALAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IPCALAB had negative earnings growth (-22.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).
Return on Equity
High ROE: IPCALAB's Return on Equity (16%) is considered low.
Discover strong past performing companies
How is Ipca Laboratories's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: IPCALAB's short term assets (₹44.6B) exceed its short term liabilities (₹14.7B).
Long Term Liabilities: IPCALAB's short term assets (₹44.6B) exceed its long term liabilities (₹6.0B).
Debt to Equity History and Analysis
Debt Level: IPCALAB has more cash than its total debt.
Reducing Debt: IPCALAB's debt to equity ratio has reduced from 29.1% to 14.2% over the past 5 years.
Debt Coverage: IPCALAB's debt is well covered by operating cash flow (108.2%).
Interest Coverage: IPCALAB's interest payments on its debt are well covered by EBIT (140x coverage).
Discover healthy companies
What is Ipca Laboratories's current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IPCALAB's dividend (0.45%) is higher than the bottom 25% of dividend payers in the Indian market (0.43%).
High Dividend: IPCALAB's dividend (0.45%) is low compared to the top 25% of dividend payers in the Indian market (1.85%).
Stability and Growth of Payments
Stable Dividend: IPCALAB's dividend payments have been volatile in the past 10 years.
Growing Dividend: IPCALAB's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (11.5%), IPCALAB's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (26.9%), IPCALAB's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Premchand Godha (75 yo)
Mr. Premchand Godha, CA, B.Com., A.C.A., has been the Managing Director of Ipca Laboratories Limited since 1983 and serves as its Chief Executive Officer. Mr. Godha was in professional practice for five ye...
CEO Compensation Analysis
Compensation vs Market: Premchand's total compensation ($USD1.37M) is above average for companies of similar size in the Indian market ($USD641.14K).
Compensation vs Earnings: Premchand's compensation has been consistent with company performance over the past year.
Experienced Board: IPCALAB's board of directors are seasoned and experienced ( 11.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ipca Laboratories Limited's employee growth, exchange listings and data sources
- Name: Ipca Laboratories Limited
- Ticker: IPCALAB
- Exchange: NSEI
- Founded: 1949
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹227.408b
- Shares outstanding: 253.70m
- Website: https://www.ipca.com
Number of Employees
- Ipca Laboratories Limited
- 125, Kandivli Industrial Estate
- Kandivli (West)
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.